- Dual CRISPR Gene Editing Strategy Cures Animals of HIV-1 Genetic Engineering & Biotechnology News
- UNMC, Temple research increases chances of eliminating HIV infection University of Nebraska Medical Center
- Dual CRISPR therapy plus long-acting ART eliminates HIV in mice FierceBiotech
- CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice | Proceedings of the National Academy of Sciences pnas.org
- Chances of eliminating HIV infection increased by novel dual gene-editing approach Medical Xpress
- View Full Coverage on Google News
Tag Archives: Biotechnology
Aging can be reversed in mice. Are people next?
CNN
—
In Boston labs, old, blind mice have regained their eyesight, developed smarter, younger brains and built healthier muscle and kidney tissue. On the flip side, young mice have prematurely aged, with devastating results to nearly every tissue in their bodies.
The experiments show aging is a reversible process, capable of being driven “forwards and backwards at will,” said anti-aging expert David Sinclair, a professor of genetics in the Blavatnik Institute at Harvard Medical School and codirector of the Paul F. Glenn Center for Biology of Aging Research.
Our bodies hold a backup copy of our youth that can be triggered to regenerate, said Sinclair, the senior author of a new paper showcasing the work of his lab and international scientists.
The combined experiments, published for the first time Thursday in the journal Cell, challenge the scientific belief aging is the result of genetic mutations that undermine our DNA, creating a junkyard of damaged cellular tissue that can lead to deterioration, disease and death.
“It’s not junk, it’s not damage that causes us to get old,” said Sinclair, who described the work last year at Life Itself, a health and wellness event presented in partnership with CNN.
“We believe it’s a loss of information — a loss in the cell’s ability to read its original DNA so it forgets how to function — in much the same way an old computer may develop corrupted software. I call it the information theory of aging.”
Jae-Hyun Yang, a genetics research fellow in the Sinclair Lab who coauthored the paper, said he expects the findings “will transform the way we view the process of aging and the way we approach the treatment of diseases associated with aging.”
While DNA can be viewed as the body’s hardware, the epigenome is the software. Epigenes are proteins and chemicals that sit like freckles on each gene, waiting to tell the gene “what to do, where to do it, and when to do it,” according to the National Human Genome Research Institute.
The epigenome literally turns genes on and off. That process can be triggered by pollution, environmental toxins and human behaviors such as smoking, eating an inflammatory diet or suffering a chronic lack of sleep. And just like a computer, the cellular process becomes corrupted as more DNA is broken or damaged, Sinclair said.
“The cell panics, and proteins that normally would control the genes get distracted by having to go and repair the DNA,” he explained. “Then they don’t all find their way back to where they started, so over time it’s like a Ping-Pong match, where the balls end up all over the floor.”
In other words, the cellular pieces lose their way home, much like a person with Alzheimer’s.
“The astonishing finding is that there’s a backup copy of the software in the body that you can reset,” Sinclair said. “We’re showing why that software gets corrupted and how we can reboot the system by tapping into a reset switch that restores the cell’s ability to read the genome correctly again, as if it was young.”
It doesn’t matter if the body is 50 or 75, healthy or wracked with disease, Sinclair said. Once that process has been triggered, “the body will then remember how to regenerate and will be young again, even if you’re already old and have an illness. Now, what that software is, we don’t know yet. At this point, we just know that we can flip the switch.”
The hunt for the switch began when Sinclair was a graduate student, part of a team at the Massachusetts Institute of Technology that discovered the existence of genes to control aging in yeast. That gene exists in all creatures, so there should be a way to do the same in people, he surmised.
To test the theory, he began trying to fast-forward aging in mice without causing mutations or cancer.
“We started making that mouse when I was 39 years old. I’m now 53, and we’ve been studying that mouse ever since,” he said. “If the theory of information aging was wrong, then we would get either a dead mouse, a normal mouse, an aging mouse or a mouse that had cancer. We got aging.”
With the help of other scientists, Sinclair and his Harvard team have been able to age tissues in the brain, eyes, muscle, skin and kidneys of mice.
To do this, Sinclair’s team developed ICE, short for inducible changes to the epigenome. Instead of altering the coding sections of the mice’s DNA that can trigger mutations, ICE alters the way DNA is folded. The temporary, fast-healing cuts made by ICE mimic the daily damage from chemicals, sunlight and the like that contribute to aging.
ICE mice at one year looked and acted twice their age.
Now it was time to reverse the process. Sinclair Lab geneticist Yuancheng Lu created a mixture of three of four “Yamanaka factors,” human adult skin cells that have been reprogrammed to behave like embryonic or pluripotent stem cells, capable of developing into any cell in the body.
The cocktail was injected into damaged retinal ganglion cells at the back of the eyes of blind mice and switched on by feeding mice antibiotics.
“The antibiotic is just a tool. It could be any chemical really, just a way to be sure the three genes are switched on,” Sinclair told CNN previously. “Normally they are only on in very young, developing embryos and then turn off as we age.”
The mice regained most of their eyesight.
Next, the team tackled brain, muscle and kidney cells, and restored those to much younger levels, according to the study.
“One of our breakthroughs was to realize that if you use this particular set of three pluripotent stem cells, the mice don’t go back to age zero, which would cause cancer or worse,” Sinclair said. “Instead, the cells go back to between 50% and 75% of the original age, and they stop and don’t get any younger, which is lucky. How the cells know to do that, we don’t yet understand.”
Today, Sinclair’s team is trying to find a way to deliver the genetic switch evenly to each cell, thus rejuvenating the entire mouse at once.
“Delivery is a technical hurdle, but other groups seem to have done well,” Sinclair said, pointing to two unpublished studies that appear to have overcome the problem.
“One uses the same system we developed to treat very old mice, the equivalent of an 80-year-old human. And they still got the mice to live longer, which is remarkable. So they’ve kind of beaten us to the punch in that experiment,” he said.
“But that says to me the rejuvenation is not just affecting a few organs, it’s able to rejuvenate the whole mouse because they’re living longer,” he added. “The results are a gift and confirmation of what our paper is saying.”
What’s next? Billions of dollars are being poured into anti-aging, funding all sorts of methods to turn back the clock.
In his lab, Sinclair said his team has reset the cells in mice multiple times, showing that aging can be reversed more than once, and he is currently testing the genetic reset in primates. But decades could pass before any anti-aging clinical trials in humans begin, get analyzed and, if safe and successful, scaled to the mass needed for federal approval.
But just as damaging factors can disrupt the epigenome, healthy behaviors can repair it, Sinclair said.
“We know this is probably true because people who have lived a healthy lifestyle have less biological age than those who have done the opposite,” he said.
His top tips? Focus on plants for food, eat less often, get sufficient sleep, lose your breath for 10 minutes three times a week by exercising to maintain your muscle mass, don’t sweat the small stuff and have a good social group.
“The message is every day counts,” Sinclair said. “How you live your life even when you’re in your teens and 20s really matters, even decades later, because every day your clock is ticking.”
250,000 kindergartners are vulnerable due to drop in vaccination rate
Nearly a quarter of a million kindergartners are vulnerable to measles due to a dip in vaccination coverage during the pandemic, according to the Centers for Disease Control and Prevention.
The CDC, in a report published Thursday, found that 93% of kindergartners were up to date with state-required vaccines during the 2021-22 school year, a decline of 2% from 2019-20.
“While this might not sound significant, it means nearly 250,000 kindergartners are potentially not protected against measles,” Dr. Georgina Peacock, head of the CDC’s immunization services division, said during a call with reporters Thursday.
“And we know that measles, mumps and rubella vaccination coverage for kindergartners is the lowest it has been in over a decade,” Peacock said.
Kindergartners are required to be vaccinated against measles, mumps and rubella; chickenpox; polio; and diphtheria, tetanus and pertussis. The vaccination rate for measles, mumps and rubella was 93.5% during the 2021-22 school year, below the target coverage of 95% to prevent outbreaks.
An ongoing measles outbreak in Columbus, Ohio, has spread to 83 children, 33 of whom were hospitalized. None of the children have died. The overwhelming majority of the kids, 78, were not vaccinated.
“These outbreaks harm children and cause significant disruptions in their opportunities to learn and grow and thrive,” said Dr. Sean O’Leary, who heads the American Academy of Pediatrics committee on infectious disease. “This is alarming and it should be a call to action for all of us.”
The CDC report looked at whether the kindergartners had received the second dose of their measles, mumps and rubella vaccine. Two doses are 97% effective at preventing disease and one dose is about 93% effective, according to the CDC.
Measles is a highly contagious virus that spreads when someone coughs or sneezes and contaminates the air, where the virus can linger for up to two hours. It can also spread when a person touches a contaminated surface and then touches their eyes, nose or mouth.
The virus is so contagious that a single person can spread the virus to 90% of people close to them who do not have immunity through vaccination or a previous infection, according to the CDC.
Measles can be dangerous for children younger than 5, adults older than 20, pregnant women, and people with compromised immune systems.
About 1 in 5 unvaccinated people who catch it are hospitalized. About 1 in 20 kids get pneumonia, and one in 1,000 have brain swelling that can cause disabilities. Symptoms begin with a high fever, cough, runny nose and red eyes. White spots appear in the mouth two to three days later, and a rash breaks out on the body.
CDC officials said disruptions to schools and the health-care system during the Covid pandemic are largely responsible for the decline in vaccination rates.
“We know that the pandemic really had a disruption to health-care systems,” Peacock said. “Part of it is that well-child visits maybe were missed and people are still trying to catch up on those well-child visits.”
“We know that the schools had a lot of things to focus on and in some cases maybe they were not able to gather all that documentation on the vaccinations,” Peacock said. “Or because children were at home for a lot of the pandemic, that may have not been the emphasis while they were focused on testing and doing all those other things related to the pandemic.”
In a separate report published Thursday, the CDC found that coverage for what’s known as the combined seven-vaccine series actually increased slightly among children born in 2018-19 by the time they turned two, compared with kids born in 2016-17.
This seven-vaccine series includes shots against measles, chickenpox, polio, hepatitis B, streptococcus pneumoniae, haemophilus influenzae or Hib, and diphtheria, tetanus and pertussis.
However, the CDC found that there were major income and racial disparities. Vaccination coverage declined by up to 5% during the pandemic for those living below the poverty level or in rural areas. Black and Hispanic children had lower vaccination rates than white children.
O’Leary said that while misinformation about vaccines is a problem, the vast majority of parents are still getting their kids vaccinated. He said inequality is the bigger issue.
“The things we really need to focus on are addressing access and child poverty,” O’Leary said.
omicron XBB.1.5 is immune evasive, binds better to cells
Gilnature | Istock | Getty Images
The Covid omicron XBB.1.5 variant is rapidly becoming dominant in the U.S. because it is highly immune evasive and appears more effective at binding to cells than related subvariants, scientists say.
XBB.1.5 now represents about 41% of new cases nationwide in the U.S., nearly doubling in prevalence over the past week, according to the data published Friday by the Centers for Disease Control and Prevention. The subvariant more than doubled as a share of cases every week through Dec. 24. In the past week, it nearly doubled from 21.7% prevalence.
Scientists and public health officials have been closely monitoring the XBB subvariant family for months because the strains have many mutations that could render the Covid-19 vaccines, including the omicron boosters, less effective and cause even more breakthrough infections.
XBB was first identified in India in August. It quickly become dominant there, as well as in Singapore. It has since evolved into a family of subvariants including XBB.1 and XBB.1.5.
Andrew Pekosz, a virologist at Johns Hopkins University, said XBB.1.5 is different from its family members because it has an additional mutation that makes it bind better to cells.
“The virus needs to bind tightly to cells to be more efficient at getting in and that could help the virus be a little bit more efficient at infecting people,” Pekosz said.
Yunlong Richard Cao, a scientist and assistant professor at Peking University, published data on Twitter Tuesday that indicated XBB.1.5 not only evades protective antibodies as effectively as the XBB.1 variant, which was highly immune evasive, but also is better at binding to cells through a key receptor.
Scientists at Columbia University, in a study published earlier this month in the journal Cell, warned that the rise of subvariants such as XBB could “further compromise the efficacy of current COVID-19 vaccines and result in a surge of breakthrough infections as well as re-infections.”
The XBB subvariants are also resistant to Evusheld, an antibody cocktail that many people with weak immune systems rely on for protection against Covid infection because they don’t mount a strong response to the vaccines.
The scientists described the resistance of the XBB subvariants to antibodies from vaccination and infection as “alarming.” The XBB subvariants were even more effective at dodging protection from the omicron boosters than the BQ subvariants, which are also highly immune evasive, the scientists found.
Dr. David Ho, an author on the Columbia study, agreed with the other scientists that XBB.1.5 probably has a growth advantage because it binds better to cells than its XBB relatives. Ho also said XBB.1.5 is about as immune evasive as XBB and XBB.1, which were two of the subvariants most resistant to protective antibodies from infection and vaccination so far.
Dr. Anthony Fauci, who is leaving his role as White House chief medical advisor, has previously said that the XBB subvariants reduce the protection the boosters provide against infection “multifold.”
“You could expect some protection, but not the optimal protection,” Fauci told reporters during a White House briefing in November.
Fauci said he was encouraged by the case of Singapore, which had a major surge of infections from XBB but did not see hospitalizations rise at the same rate. Pekosz said XBB.1.5, in combination with holiday travel, could cause cases to rise in the U.S. But he said the boosters appear to be preventing severe disease.
“It does look like the vaccine, the bivalent booster is providing continued protection against hospitalization with these variants,” Pekosz said. “It really emphasizes the need to get a booster particularly into vulnerable populations to provide continued protection from severe disease with these new variants.”
Health officials in the U.S. have repeatedly called on the elderly in particular to make sure they are up to date on their vaccines and get treated with the antiviral Paxlovid if they have a breakthrough infection.
CDC expands BMI charts for severely overweight kids
The Centers for Disease Control and Prevention on Thursday released new body mass index charts for children in response to the growing obesity crisis in the U.S.
The previous BMI chart for children ages 2 to 19, published in 2000, is based on data from 1963 to 1980, but obesity and severe obesity in children has increased significantly since the ’80s. More than 4.5 million children and teenagers had severe obesity in 2018, according to the CDC.
BMI is calculated using a mathematical formula that measures body fat, generally by dividing an individual’s height by their weight. For adults, a healthy BMI runs from 18.5 to 24.9, or 111 lbs. to about 150 lbs. for someone who is 5’5″. At 5’10”, a healthy BMI runs between 129 lbs. and 175 lbs. For adults ages 20 and older, a BMI of 30 and above is considered obese.
The previous charts for children did not go beyond a BMI of 37. The new charts extend to a BMI of 60 and measure whether it falls within healthy parameters based on a percentile measured against other children of the same age and gender.
“Prior to today’s release, the growth charts did not extend high enough to plot BMI for the increasing number of children with severe obesity,” said Dr. Karen Hacker, director of the CDC’s National Center for Chronic Disease Prevention and Health Promotion.
BMI for kids up to 20-year-olds runs along a sliding range, depending on age and gender. Under the new guidelines, healthy BMI for kids can range from as low as around 13 to about 17 for a 6-year-old girl or boy to a range of as much as roughly 18 to around 26 for a 20-year-old young woman.
The extended charts will help health-care providers work with families to treat children who are suffering from obesity, Hacker said. The BMI charts from 2000 will still be used for children who are not obese, according to the CDC.
Obesity has increased significantly among children over the past 40 years. During the four-year period ended in 1980, 5.5% of children ages 2 to 19 were obese and 1.3% were severely obese. By 2018, 19.3% of kids were obese and 6.1% were severely obese, according to National Center for Health Statistics.
Obesity for children is defined as a BMI that is higher than 95% of kids of the same age and gender, according to the CDC. Severe obesity is a BMI that is 120% higher than the 95th percentile.
Although children’s BMI is calculated using the same formula as adults, a healthy weight is measured in relation to other kids of the same age and gender. This is because children’s height and weight can vary significantly as they grow.
Study Links No COVID-19 Vaccination to Increased Car Crash Risk
Science has a way of presenting actual facts and connecting dots you likely didn’t see ever connecting. For instance, who would have thought to find a link between the people who decided to pass on getting vaccinated against COVID-19 and traffic accidents? A recent study published in The American Journal of Medicine shares the science behind such a link that actually exists.
In the study, Canadian researchers examined over 11 million COVID-19 vaccination records, of individuals over the age of 18, who would be licensed, from different social, economic and health backgrounds. Of those 11 million, 16 percent (1,760,000) were not vaccinated. Researchers then looked into records and identified unvaccinated individuals who might have diseases linked to traffic risks like dementia, diabetes, sleep apnea and alcohol abuse — and then looked into the traffic accident side of things. Those situations included incidents that sent patients to the emergency room, time and day, ambulance involvement and a “triage severity score.”
With all those parameters considered, researchers were able to identify that individuals who hadn’t gotten a COVID-19 vaccine were at a greater risk of traffic accidents. But it wasn’t because of the vaccine. The link actually comes down to risks associated with decision making—in relation to decisions concerning getting vaccinated, and also to obey (or not obey) traffic laws.
Of course, this isn’t saying that if you didn’t get a shot you’re going to get into or cause a traffic incident. The correlation doesn’t work that way. However, researchers concluded if an individual was hesitant or unwilling to “protect themselves” with the vaccine, these same people would be more likely to have no regard for traffic laws. And the data is there to back it up.
Of the unvaccinated, 72 percent were more likely to be involved in a severe car accident. These numbers look worse when the study pointed out that the percentage was “ similar to the relative risk associated with sleep apnea” but still not as bad as those who abused alcohol. But the risk is still there, so much so that the study said that the risk “exceeds the safety gains from modern automobile engineering advances and also imposes risks on other road users.”
One thing the study did admit was that “correlation does not mean causality.” The study didn’t try to touch on whether or not there was a link between not getting the vaccine and driving recklessly. But the authors of the study did speculate.
One possibility relates to a distrust of government or belief in freedom that contributes to both vaccination preferences and increased traffic risks. A different explanation might be misconceptions of everyday risks, faith in natural protection, antipathy toward regulation, chronic poverty, exposure to misinformation, insufficient resources, or other personal beliefs. Alternative factors could include political identity, negative past experiences, limited health literacy, or social networks that lead to misgivings around public health guidelines. These subjective unknowns remain topics for more research.”
If you want to know more you can read more about the study and its results here.
BQ, XBB omicron subvariants pose serious threat to boosters
Evusheld injection, a new COVID treatment that people can take before becoming symptomatic, in Chicago on Friday, Feb. 4, 2022.
Chris Sweda | Tribune News Service | Getty Images
The omicron subvariants that have become dominant in recent months present a serious threat to the effectiveness of the new boosters, render antibody treatments ineffective and could cause a surge of breakthrough infections, according to a new study.
The BQ.1, BQ.1.1, XBB and XBB.1 omicron subvariants are the most immune evasive variants of Covid-19 to date, according to scientists affiliated with Columbia University and the University of Michigan. These variants, taken together, are causing 72% of new infections in the U.S. right now, according to data from the Centers for Disease Control and Prevention.
related investing news
The scientists, in a study published online Tuesday in the peer-reviewed journal Cell, found that these subvariants are “barely susceptible to neutralization” by the vaccines, including the new omicron boosters. The immune response of people who were vaccinated and had breakthrough infections with prior omicron variants was also weaker against the subvariants.
“Together, our findings indicate that BQ and XBB subvariants present serious threats to current COVID-19 vaccines, render inactive all authorized antibodies, and may have gained dominance in the population because of their advantage in evading antibodies,” the scientists wrote.
Although these subvariants are more likely to cause breakthrough infections, the vaccines have been shown to remain effective at preventing hospitalization and severe disease from omicron, the scientists wrote.
The study examined blood samples from people who received three or four shots of the original vaccines, those who received the new omicron boosters after three shots of the original vaccines, and individuals vaccinated with the original shots who also had breakthrough infections from the BA.2 or BA.5 subvariants.
For people who received the omicron boosters, antibodies that block infection were 24 times lower against BQ.1, 41 times lower against BQ.1.1, 66 times lower against XBB and 85 times lower against XBB.1 compared to their performance against the ancestral strain that emerged in Wuhan, China in 2019.
However, people who received the omicron boosters had modestly higher antibody levels against all of these subvariants compared with people who received three or four shots of the original vaccines, according to the study.
People who were vaccinated and had breakthrough infections had the highest antibody levels of any group in the study, though neutralization was also much lower against the subvariants than the ancestral strain.
The subvariants have evolved away from previous versions of omicron in dramatic fashion. BQ.1.1, for example, is about as different from omicron BA.5 as the latter subvariant is from ancestral Covid strain, according to the study.
“Therefore, it is alarming that these newly emerged subvariants could further compromise the efficacy of current COVID-19 vaccines and result in a surge of breakthrough infections, as well as re-infections,” the scientists wrote.
XBB.1, however, presents the biggest challenge. It is about 49 times more resistant to antibody neutralization than the BA.5 subvariant, according to the study. XBB.1, fortunately, is currently causing no more than 1% of infections in the U.S., according to CDC data.
BQ.1.1 and BQ.1 represent 37% and 31% of new infections respectively, while XBB is causing 4.7% of new infections, according to CDC data.
Antibodies ineffective
Key antibody drugs, Evusheld and bebtelovimab, were “completely inactive” against the new subvariants, according to the study. These antibodies are used primarily by people with weak immune systems.
Evusheld is an antibody cocktail used to prevent Covid in people with weak immune systems who don’t respond strongly to the vaccines. Bebtelovimab is used to prevent Covid from progressing to severe disease in organ transplant patients and other individuals who cannot take other treatments.
“This poses a serious problem for millions of immunocompromised individuals who do not respond robustly to COVID-19 vaccines,” the scientists wrote. “The urgent need to develop active monoclonal antibodies for clinical use is obvious.”
The FDA has already pulled its authorization of bebtelovimab nationwide because it is no longer effective against the dominant omicron variants in the U.S. Evusheld remains authorized as the only option for pre-exposure prophylaxis.
New Covid infections increased by about 50% to 459,000 for the week ending Dec. 7, according to CDC data. Covid deaths increased 61% to nearly 3,000 during the same week. Hospital admissions have plateaued at 4,700 per day on average after rising in November, according to the data.
White House chief medical advisor Dr. Anthony Fauci, in a press briefing last month, said U.S. health officials are hoping there’s enough immunity in the population from vaccination, infection or both to prevent the massive surge of infections and hospitalizations the U.S. suffered last winter when omicron first arrived.
Amgen in Advanced Talks to Buy Horizon Therapeutics
Amgen Inc.
AMGN -2.42%
is in advanced talks to buy drug company
Horizon Therapeutics
HZNP 0.39%
PLC, according to people familiar with the matter, in a takeover likely to be valued at well over $20 billion and mark the largest healthcare merger of the year.
The U.S. biotechnology company was the last of three suitors standing in an auction for Horizon, the people said, after French drugmaker
Sanofi SA
said Sunday it was out of the running.
A deal could be finalized by Monday assuming the talks with Amgen don’t fall apart, the people said.
Horizon develops medicines to treat rare autoimmune and severe inflammatory diseases that are currently sold mostly in the U.S. Its biggest drug, Tepezza, is used to treat thyroid eye disease, an affliction characterized by progressive inflammation and damage to tissues around the eyes.
The company is Nasdaq-listed, but based in Ireland and has operations in Dublin, Deerfield, Ill., and a new facility in Rockville, Md.
Horizon said last month it was fielding takeover interest from Amgen, Sanofi and
Johnson & Johnson,
a disclosure prompted by a Wall Street Journal report.
Johnson & Johnson later said it had dropped out.
Last year, revenue from Tepezza more than doubled, driving Horizon’s overall net sales 47% higher to $3.23 billion. Horizon has said that annual global net sales of the drug are targeted to eventually peak at more than $4 billion as the company aims to win approval to sell it in Europe and Japan.
That type of growth is attractive to big drug companies—with many sitting on big piles of cash—that rely on acquisitions as a key strategy to expand sales. Many big drugmakers are looking for new sources of revenue to offset losses when some of their main products lose patent protection.
Analysts expect Amgen will lose sales when patents begin expiring on its big-selling osteoporosis drugs Prolia and Xgeva later this decade. The pair of drugs accounted for nearly $5.3 billion of Amgen’s $26 billion in revenue last year.
In October, Amgen completed a $3.7 billion deal for ChemoCentryx and its drug to treat a rare immune-system disease.
Adding Horizon would provide more rare immune-disease drugs to Amgen’s lineup, which also includes the biotech’s Enbrel and Otezla immune-disease therapies. Amgen could help sell more of Horizon’s products overseas, according to analysts.
Acquiring Horizon could add about $4 billion in new revenue for Amgen by 2024, according to Jefferies & Co.
Other big life-sciences companies have been inking deals in recent months.
Johnson & Johnson recently struck a $16.6 billion deal to acquire heart device maker Abiomed Inc. to bolster sales of its medical-gear division, which had been lagging behind those of its pharmaceutical unit.
Merck
& Co. followed with a deal of its own, agreeing to buy blood-cancer biotech
Imago BioSciences Inc.
for $1.35 billion, ahead of the patent expiration of its cancer immunotherapy Keytruda.
Pfizer Inc.,
meanwhile, agreed in August to buy Global Blood Therapeutics Inc. for $5.4 billion, in a deal that would give the big drugmaker a foothold in the treatment of sickle-cell disease.
A deal for Horizon would likely rank as the largest healthcare acquisition globally in 2022, ahead of the Johnson & Johnson-Abiomed tie-up. The selloff in stocks this year amid rising interest rates, while putting a damper on deal activity, has also made some companies more attractive targets. At the stock’s peak about a year ago, Horizon was valued at roughly $27 billion.
The shares, which fell sharply earlier this year, have surged since the possibility of a takeover surfaced, and the company now has a market value of about $22 billion.
Horizon’s other drugs include Krystexxa for treating gout, a form of inflammatory arthritis, and Ravicti for a rare, potentially life-threatening genetic disease known as urea cycle disorder that raises ammonia levels in the blood.
Drugs treating rare diseases have emerged as a large source of pharmaceutical sales because they can command high prices that health insurers have been willing to pay.
Write to Ben Dummett at ben.dummett@wsj.com, Dana Cimilluca at dana.cimilluca@wsj.com and Laura Cooper at laura.cooper@wsj.com
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
CDC encourages people to wear masks to prevent spread of Covid, flu, RSV
The Centers for Disease Control Prevention on Monday encouraged people to wear masks to help reduce the spread of respiratory illnesses this season as Covid, flu and RSV circulate at the same time.
CDC Director Dr. Rochelle Walensky, in a call with reporters, said wearing a mask is one of several everyday precautions that people can take to reduce their chances of catching or spreading a respiratory virus during the busy holiday season.
“We also encourage you to wear a high-quality, well-fitting mask to prevent the spread of respiratory illnesses,” said Walensky, adding that people living in areas with high levels of Covid transmission should especially consider masking.
The CDC director said the agency is considering expanding its system of Covid community levels to take into account other respiratory viruses such as the flu. The system is the basis for when CDC advises the public to wear masks. But Walensky encouraged people to take proactive action.
“One need not wait on CDC action in order to put a mask on,” Walensky said. “We would encourage all of those preventive measures — hand washing, staying home when you’re sick, masking, increased ventilation — during respiratory virus season, but especially in areas of high Covid-19 community levels.”
About 5% of the U.S. population lives in counties where the CDC is officially recommending masks due to high Covid levels. The CDC continues to recommend masking for anyone travelling by plane, train, bus or other forms of public transportation, Walensky said.
People with weak immune systems and those who otherwise face a heightened risk of severe disease should also consider wearing a mask, the CDC director said.
Walensky strongly encouraged everyone eligible to receive their flu shot and Covid booster. Flu vaccination coverage is lagging for at-risk groups — children under age 5, pregnant women, and at-risk seniors — compared with last year, the CDC director said. There is no vaccine for RSV.
“I want to emphasize that the flu vaccine can be life saving and importantly, there’s still time to get vaccinated to be protected against flu this season and its potential serious consequences,” Walensky said.
The flu has arrived early and hit the U.S. hard with hospitalizations at a decade high for this time of year. More than 8.7 million people have fallen ill, 78,000 have been hospitalized, and 4,500 people have died from the flu this season, according to CDC data. Fourteen children have died from the flu so far this season.
More than 19,000 people were hospitalized with the flu during the week ending Nov. 26, nearly double the previous week, according to CDC data.
People hospitalized with Covid also increased 27% during the week ending Dec. 2, according to CDC data. And respiratory syncytial virus, or RSV, has been hospitalizing children at higher rate than in previous years. Walensky said RSV appears to have peaked in the Southeast and may be leveling off in the Mid-Atlantic, though circulation of the virus remains high in much of the nation.
“We now face yet another surge of illness. Another moment of overstretched capacity and really one of tragic and often preventable death,” Walensky said, as she thanked health-care workers for their service during the repeated surges of illness they have confronted since the Covid pandemic began.
Dr. Sandra Fryhofer, board chair of the American Medical Association, said the circulation of Covid, flu and RSV at the same is a “a perfect storm for a terrible holiday season.” Fryhofer said she understands many people are tired of receiving repeated Covid shots, but getting vaccinated is the best way to avoiding falling ill over the holidays.
“You could get really, really sick this year and ruin your holiday celebrations if you don’t get vaccinated,” Fryhofer said during Monday’s call.
The Children’s Hospital Association and the American Academy of Pediatrics last month asked the Biden administration to declare a public health emergency in response to the surge of pediatric hospitalizations from RSV and the flu.
Biden administration will end monkeypox public health emergency
People line up to get a monkeypox vaccination at a new walk-up monkeypox vaccination site at Barnsdall Art Park on Tuesday, Aug. 9, 2022 in Hollywood, CA.
Brian Van Der Brug | Los Angeles Times | Getty Images
The Biden administration will end the public health emergency declared in response to the monkeypox outbreak, as new infections have declined dramatically and vaccination rates have increased.
The Health and Human Services Department does not expect it will renew the emergency declaration after it expires on Jan. 31 “given the low number of cases today,” HHS Secretary Xavier Becerra said in a statement Friday.
“But we won’t take our foot off the gas — we will continue to monitor the case trends closely and encourage all at-risk individuals to get a free vaccine,” he said. “As we move into the next phase of this effort, the Biden-Harris Administration continues working closely with jurisdictions and partners to monitor trends, especially in communities that have been disproportionately affected.”
Becerra declared an emergency in August in an effort to accelerate a vaccination and education campaign as the virus was spreading swiftly in the gay community. The spread of the virus, dubbed “mpox” on Monday by the World Health Organization in order to reduce stigma associated with its name, has slowed drastically since.
Mpox has infected nearly 30,000 people and killed 15 in the U.S. since health officials confirmed the first domestic case in May, according to the Centers for Disease Control and Prevention. The U.S. outbreak is the largest in the world.
But infections have slowed dramatically since August, when new cases peaked at 638 per day on average. The U.S. is currently averaging about seven new cases a day, according to CDC data.
U.S. health officials have said the outbreak has slowed because vaccinations have increased dramatically, and people have changed their behavior in response to education campaigns about how to avoid infection.
The vaccination campaign got off to a rocky start, with limited supplies resulting in long lines at clinics and protests in some cities. But vaccinations increased significantly after the White House created a task force and HHS declared a public health emergency.
More than 1.1 million doses of the Jynneos vaccine have been administered in the U.S. since the summer. CDC Director Dr. Rochelle Walensky has said about 1.7 million gay and bisexual people who are HIV positive or are taking medication to prevent HIV infection are at highest risk from mpox.
Mpox has spread primarily through sexual contact among men who have sex with men. The virus causes rashes resembling pimples or blisters that can develop in sensitive areas and be very painful. Though mpox is rarely fatal, people with compromised immune systems are at higher risk of severe disease.
The CDC, in a report published in late October, said it is unlikely the U.S. will eradicate mpox in the near future. The virus will probably continue to circulate at low level primarily in communities of men who have sex with men, according to CDC. Though anyone can catch mpox, there’s little evidence of the virus spreading widely in the general population so far, according to CDC.
The global mpox outbreak this year is the largest in history with more than 80,000 confirmed cases in more than 100 countries. The current outbreak is highly unusual because the virus is spreading widely between people in Europe and North America.
Historically, mpox spread at low levels in remote areas of West and Central Africa where people caught the virus from infected animals.